Recombinant Human IL-6R alpha Protein

Formulations:
Catalog # Availability Size / Price Qty
227-SR-025
Recombinant Human IL-6R alpha Protein Data
2 Images
Product Details
Citations (35)
FAQs
Reviews (1)

Recombinant Human IL-6R alpha Protein Summary

Purity
>97%, by SDS-PAGE under reducing conditions and visualized by silver stain.
Endotoxin Level
<1.0 EU per 1 μg of the protein by the LAL method.
Activity
Measured by its ability to enhance the IL-6 activity on M1 mouse myeloid leukemia cells. Saito, T. et al. (1991) J. Immunol. 147:168. The ED50 for this effect is 5.0-15.0 ng/mL.
Source
Spodoptera frugiperda, Sf 21 (baculovirus)-derived human IL-6R alpha protein
Leu20-Asp358
Accession #
N-terminal Sequence
Analysis
Leu20
Predicted Molecular Mass
38 kDa
SDS-PAGE
45-50 kDa, reducing conditions

Product Datasheets

Carrier Free

What does CF mean?

CF stands for Carrier Free (CF). We typically add Bovine Serum Albumin (BSA) as a carrier protein to our recombinant proteins. Adding a carrier protein enhances protein stability, increases shelf-life, and allows the recombinant protein to be stored at a more dilute concentration. The carrier free version does not contain BSA.

What formulation is right for me?

In general, we advise purchasing the recombinant protein with BSA for use in cell or tissue culture, or as an ELISA standard. In contrast, the carrier free protein is recommended for applications, in which the presence of BSA could interfere.

227-SR

Formulation Lyophilized from a 0.2 μm filtered solution in PBS with BSA as a carrier protein.
Reconstitution Reconstitute at 100 μg/mL in sterile PBS containing at least 0.1% human or bovine serum albumin.
Shipping The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.

227-SR/CF

Formulation Lyophilized from a 0.2 μm filtered solution in PBS.
Reconstitution Reconstitute at 100 μg/mL in sterile PBS.
Shipping The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.

Data Images

Bioactivity View Larger

Recombinant Human IL-6R alpha (Catalog # 227-SR) enhances the IL-6 activity on the M1 mouse myeloid leukemia cell line. The ED50for this effect is 5-15 ng/mL.

SDS-PAGE View Larger

1 μg/lane of Recombinant Human IL6R alpha was resolved with SDS-PAGE under reducing (R) conditions and visualized by silver staining, showing a single band at 45-50 kDa.

Reconstitution Calculator

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Background: IL-6R alpha

The multifunctional factor interleukin 6 (IL-6) exerts its activities through binding to a high-affinity receptor complex consisting of two membrane glycoproteins: an 80 kDa component receptor that binds IL-6 with low affinity (IL-6R alpha ) and a signal-transducing component of 130 kDa (gp130) that does not bind IL-6 by itself, but is required for high-affinity binding of IL-6 by the complex. Both components of the receptor complex, IL-6R alpha and gp130 have been cloned, sequenced, and expressed (1-4).

A soluble form of the IL-6R alpha has been found in the urine of healthy adult humans (5). This soluble receptor apparently arises from proteolytic cleavage of membrane-bound IL-6R alpha. No naturally-occurring mRNA encoding a truncated form of the IL-6R alpha has been reported. Soluble forms of human and murine IL-6R alpha s have been constructed, however, by insertion of termination codons into the regions of the IL-6R alpha cDNAs encoding the external portions of the receptors and prior to the transmembrane domains. These soluble receptors have been expressed in COS-7 and CHO cells and have been shown to bind to IL-6 in solution and to augment the activity of IL-6 as a result of the binding of the IL-6/IL-6R alpha complex to membrane-bound gp130 (6, 7).

References
  1. Yamasaki et al. (1988) Science 241:825.
  2. Baumann et al. (1990) J. Biol. Chem. 265:19853.
  3. Hibi et al. (1990) Cell 63:1149.
  4. Schooltink et al. (1991) Eur. J. Biochem. 277:659.
  5. Novick et al. (1989) J. Exp. Med. 170:1409.
  6. Yasukawa et al. (1990) J. Biochem. 108:673.
  7. Saito et al. (1991) J. Immunology 147:168.
Long Name
Interleukin 6 Receptor alpha
Entrez Gene IDs
3570 (Human); 16194 (Mouse); 24499 (Rat); 102116430 (Cynomolgus Monkey)
Alternate Names
CD126; gp80; IL-6 R alpha; IL6Q; IL6R alpha; IL-6R alpha; IL6R; IL-6R-1; IL6RA; IL-6Ra; IL6RQ; interleukin 6 receptor

Citations for Recombinant Human IL-6R alpha Protein

R&D Systems personnel manually curate a database that contains references using R&D Systems products. The data collected includes not only links to publications in PubMed, but also provides information about sample types, species, and experimental conditions.

35 Citations: Showing 1 - 10
Filter your results:

Filter by:

  1. Treatment of type 2 diabetes with the designer cytokine IC7Fc
    Authors: M Findeisen, TL Allen, DC Henstridge, H Kammoun, AE Brandon, LL Baggio, KI Watt, M Pal, L Cron, E Estevez, C Yang, GM Kowalski, L O'Reilly, C Egan, E Sun, LM Thai, G Krippner, TE Adams, RS Lee, J Grötzinger, C Garbers, S Risis, MJ Kraakman, NA Mellet, J Sligar, ET Kimber, RL Young, MA Cowley, CR Bruce, PJ Meikle, PA Baldock, P Gregorevic, TJ Biden, GJ Cooney, DJ Keating, DJ Drucker, S Rose-John, MA Febbraio
    Nature, 2019;574(7776):63-68.
    Species: Human
    Sample Types: Protein
    Applications: Bioassay
  2. Inhibition of Tyrosine-Phosphorylated STAT3 in Human Breast and Lung Cancer Cells by Manuka Honey is Mediated by Selective Antagonism of the IL-6 Receptor
    Authors: P Aryappalli, K Shabbiri, RJ Masad, RH Al-Marri, SM Haneefa, YA Mohamed, K Arafat, S Attoub, O Cabral-Mar, KB Ramadi, MJ Fernandez-, BK Al-Ramadi
    Int J Mol Sci, 2019;20(18):.
    Species: Insect
    Sample Types: Honey
    Applications: Bioassay
  3. IL-6 exhibits both cis and trans signaling in osteocytes and osteoblasts, but only�trans�signaling promotes bone formation and osteoclastogenesis
    Authors: NE McGregor, M Murat, J Elango, IJ Poulton, EC Walker, B Crimeen-Ir, PWM Ho, JH Gooi, TJ Martin, NA Sims
    J. Biol. Chem., 2019;0(0):.
    Species: Mouse
    Sample Types: Whole Cells
    Applications: Bioassay
  4. Interleukin-6 promotes a sustained loss of endothelial barrier function via Janus kinase-mediated STAT3 phosphorylation and de novo protein synthesis
    Authors: H Alsaffar, N Martino, JP Garrett, AP Adam
    Am. J. Physiol., Cell Physiol., 2018;0(0):.
    Species: Human
    Sample Types: Whole Cells
    Applications: Bioassay
  5. A bispecific antibody that targets IL-6 receptor and IL-17A for the potential therapy of patients with autoimmune and inflammatory diseases
    Authors: M Lyman, V Lieuw, R Richardson, A Timmer, C Stewart, S Granger, R Woods, M Silacci, D Grabulovsk, R Newman
    J. Biol. Chem., 2018;0(0):.
    Species: Human
    Sample Types: Serum
    Applications: Bioassay
  6. Fungal metabolite (+)-terrein suppresses IL-6/sIL-6R-induced CSF1 secretion by inhibiting JAK1 phosphorylation in human gingival fibroblasts
    Authors: S Yamamoto, K Omori, H Mandai, M Nakayama, S Nakagawa, H Kobayashi, T Kunimine, H Yoshimura, K Sakaida, H Sako, S Ibaragi, T Yamamoto, H Maeda, S Suga, S Takashiba
    Heliyon, 2018;4(11):e00979.
    Species: Human
    Sample Types: Whole Cells
    Applications: Bioassay
  7. Presenilin 1 Regulates NF-?B Activation via Association with Breakpoint Cluster Region and Casein Kinase II
    Authors: Y Tanaka, L Sabharwal, M Ota, I Nakagawa, JJ Jiang, Y Arima, H Ogura, M Okochi, M Ishii, D Kamimura, M Murakami
    J. Immunol., 2018;0(0):.
    Species: Mouse
    Sample Types: In Vivo
    Applications: In Vivo
  8. IL-6 potentiates BMP-2-induced osteogenesis and adipogenesis via two different BMPR1A-mediated pathways
    Authors: RL Huang, Y Sun, CK Ho, K Liu, QQ Tang, Y Xie, Q Li
    Cell Death Dis, 2018;9(2):144.
    Species: Human
    Sample Types: Whole Cells
    Applications: Bioassay
  9. SorLA in interleukin-6 signaling and turnover
    Authors: JV Larsen, CM Petersen
    Mol. Cell. Biol, 2017;0(0):.
    Species: Human
    Sample Types: Protein
    Applications: Bioassay
  10. COPD monocytes demonstrate impaired migratory ability
    Authors: AK Ravi, J Plumb, R Gaskell, S Mason, CS Broome, G Booth, M Catley, J Vestbo, D Singh
    Respir. Res., 2017;18(1):90.
    Species: Human
    Sample Types: Whole Cells
    Applications: Bioassay
  11. STAT3-induced WDR1 overexpression promotes breast cancer cell migration
    Cell Signal, 2016;0(0):.
    Species: Human
    Sample Types: Whole Cells
    Applications: Bioassay
  12. Structure-based virtual screening and characterization of a novel IL-6 antagonistic compound from synthetic compound database
    Drug Des Devel Ther, 2016;10(0):4091-4100.
    Species: Human
    Sample Types: Recombinant Protein
    Applications: Enzyme Assay
  13. A Novel IL6 Antibody Sensitizes Multiple Tumor Types to Chemotherapy Including Trastuzumab-Resistant Tumors.
    Authors: Zhong H, Davis A, Ouzounova M, Carrasco R, Chen C, Breen S, Chang Y, Huang J, Liu Z, Yao Y, Hurt E, Moisan J, Fung M, Tice D, Clouthier S, Xiao Z, Wicha M, Korkaya H, Hollingsworth R
    Cancer Res, 2016;76(2):480-90.
    Species: Human
    Sample Types: Whole Cells
    Applications: Bioassay
  14. Cytokines TNF-?, IL-6, IL-17F, and IL-4 Differentially Affect Osteogenic Differentiation of Human Adipose Stem Cells.
    Authors: Angela P Bastidas-C, Astrid D Bakker, Behrouz Zandieh-D, Cornelis J Kleverlaa, Nathalie Bravenboe, Tim Forouzanf, Jenneke Klein-Nul
    Stem Cells International, 2016;0(0):1687-966X.
    Species: Human
    Sample Types: Whole Cells
    Applications: Bioassay
  15. Interleukin 6 receptor is an independent prognostic factor and a potential therapeutic target of ovarian cancer.
    Authors: Isobe, Aki, Sawada, Kenjiro, Kinose, Yasuto, Ohyagi-Hara, Chifumi, Nakatsuka, Erika, Makino, Hiroshi, Ogura, Tomonori, Mizuno, Tomoko, Suzuki, Noriko, Morii, Eiichi, Nakamura, Koji, Sawada, Ikuko, Toda, Aska, Hashimoto, Kae, Mabuchi, Seiji, Ohta, Tsuyoshi, Morishige, Ken-ichi, Kurachi, Hirohisa, Kimura, Tadashi
    PLoS ONE, 2015;10(2):e0118080.
    Species: Human
    Sample Types: Whole Cells
    Applications: Bioassay
  16. Peroxiredoxin-2 and STAT3 form a redox relay for H2O2 signaling.
    Authors: Sobotta M, Liou W, Stocker S, Talwar D, Oehler M, Ruppert T, Scharf A, Dick T
    Nat Chem Biol, 2015;11(1):64-70.
    Species: Human
    Sample Types: Whole Cells
    Applications: Bioassay
  17. RelB/p50 complexes regulate cytokine-induced YKL-40 expression.
    Authors: Bhardwaj R, Yester J, Singh S, Biswas D, Surace M, Waters M, Hauser K, Yao Z, Boyce B, Kordula T
    J Immunol, 2015;194(6):2862-70.
    Species: Human
    Sample Types: Whole Cells
    Applications: Bioassay
  18. Protein tyrosine phosphatase PTPN9 regulates erythroid cell development through STAT3 dephosphorylation in zebrafish.
    Authors: Bu Y, Su F, Wang X, Gao H, Lei L, Chang N, Wu Q, Hu K, Zhu X, Chang Z, Meng K, Xiong J
    J Cell Sci, 2014;127(0):2761-70.
    Species: Human
    Sample Types: Whole Cells
    Applications: Bioassay
  19. Discovery and characterization of olokizumab: a humanized antibody targeting interleukin-6 and neutralizing gp130-signaling.
    Authors: Shaw S, Bourne T, Meier C, Carrington B, Gelinas R, Henry A, Popplewell A, Adams R, Baker T, Rapecki S, Marshall D, Moore A, Neale H, Lawson A
    MAbs, 2014;6(3):774-82.
    Species: Human
    Sample Types: Whole Cells
    Applications: Bioassay
  20. Interleukin-6 (IL-6) trans signaling drives a STAT3-dependent pathway that leads to hyperactive transforming growth factor-beta (TGF-beta) signaling promoting SMAD3 activation and fibrosis via Gremlin protein.
    Authors: O'Reilly S, Ciechomska M, Cant R, van Laar J
    J Biol Chem, 2014;289(14):9952-60.
    Species: Human
    Sample Types: Whole Cells
    Applications: Bioassay
  21. Blood stem cell fate regulation by Delta-1-mediated rewiring of IL-6 paracrine signaling.
    Authors: Csaszar, Elizabet, Wang, Weijia, Usenko, Tatiana, Qiao, Wenlian, Delaney, Colleen, Bernstein, Irwin D, Zandstra, Peter W
    Blood, 2014;123(5):650-8.
    Species: Human
    Sample Types: Whole Cells
    Applications: Bioassay
  22. CTR9, a component of PAF complex, controls elongation block at the c-Fos locus via signal-dependent regulation of chromatin-bound NELF dissociation.
    Authors: Yoo H, Seo J, Yoo J
    PLoS ONE, 2013;8(4):e61055.
    Species: Human
    Sample Types: Whole Cells
    Applications: Bioassay
  23. Targeting protein kinase CK2 suppresses prosurvival signaling pathways and growth of glioblastoma.
    Authors: Zheng Y, McFarland B, Drygin D, Yu H, Bellis S, Kim H, Bredel M, Benveniste E
    Clin Cancer Res, 2013;19(23):6484-94.
    Species: Human
    Sample Types: Whole Cells
    Applications: Cell Culture
  24. NF-kappaB-induced IL-6 ensures STAT3 activation and tumor aggressiveness in glioblastoma.
    Authors: McFarland B, Hong S, Rajbhandari R, Twitty G, Gray G, Yu H, Benveniste E, Nozell S
    PLoS ONE, 2013;8(11):e78728.
    Species: Human
    Sample Types: Whole Cells
    Applications: Cell Culture
  25. Soluble interleukin-6 receptor induces motor stereotypies and co-localizes with gp130 in regions linked to cortico-striato-thalamo-cortical circuits.
    Authors: Patel A, Zhu Y, Kuzhikandathil E, Banks W, Siegel A, Zalcman S
    PLoS ONE, 2012;7(7):e41623.
    Species: Mouse
    Sample Types: In Vivo
    Applications: In Vivo
  26. Oligo-guanosine nucleotide induces neuropilin-1 internalization in endothelial cells and inhibits angiogenesis.
    Authors: Narazaki M, Segarra M, Hou X, Tanaka T, Li X, Tosato G
    Blood, 2010;116(16):3099-107.
    Species: Human
    Sample Types: Recombinant Protein
    Applications: Neutralization
  27. Interleukin-6 in the bone marrow microenvironment promotes the growth and survival of neuroblastoma cells.
    Authors: Ara T, Song L, Shimada H, Keshelava N, Russell HV, Metelitsa LS, Groshen SG, Seeger RC, DeClerck YA
    Cancer Res., 2009;69(1):329-37.
    Species: Human
    Sample Types: Whole Cells
    Applications: Bioassay
  28. A novel ultra-sensitive enzyme immunoassay for soluble human insulin receptor ectodomain and its measurement in urine from healthy subjects and patients with diabetes mellitus.
    Authors: Umehara A, Nishioka M, Obata T
    Clin. Biochem., 2009;42(13):1468-75.
    Species: N/A
    Sample Types: N/A
    Applications: ELISA (Standard)
  29. Interleukin-7 stimulates secretion of S100A4 by activating the JAK/STAT signaling pathway in human articular chondrocytes.
    Authors: Yammani RR, Long D, Loeser RF
    Arthritis Rheum., 2009;60(3):792-800.
    Species: Human
    Sample Types: Whole Cells
    Applications: Bioassay
  30. Epigallocatechin-3-gallate inhibits IL-6 synthesis and suppresses transsignaling by enhancing soluble gp130 production.
    Authors: Ahmed S, Marotte H, Kwan K, Ruth JH, Campbell PL, Rabquer BJ, Pakozdi A, Koch AE
    Proc. Natl. Acad. Sci. U.S.A., 2008;105(38):14692-7.
    Species: Human
    Sample Types: Whole Cells
    Applications: Bioassay
  31. Effect of IL-6 trans-signaling on the pro-remodeling phenotype of airway smooth muscle.
    Authors: Ammit AJ, Moir LM, Oliver BG, Hughes JM, Alkhouri H, Ge Q, Burgess JK, Black JL, Roth M
    Am. J. Physiol. Lung Cell Mol. Physiol., 2007;292(1):L199-206.
    Species: Human
    Sample Types: Whole Cells
    Applications: Bioassay
  32. CD14 is an acute-phase protein.
    Authors: Bas S, Gauthier BR, Spenato U, Stingelin S, Gabay C
    J. Immunol., 2004;172(7):4470-9.
    Species: Human
    Sample Types: Whole Cells
    Applications: Bioassay
  33. trans fatty acids and systemic inflammation in heart failure.
    Authors: Mozaffarian D, Rimm EB, King IB, Lawler RL, McDonald GB, Levy WC
    Am. J. Clin. Nutr., 2004;80(6):1521-5.
    Species: N/A
    Sample Types: N/A
    Applications: ELISA (Standard)
  34. Secretion of oncostatin M by infiltrating neutrophils: regulation of IL-6 and chemokine expression in human mesothelial cells.
    Authors: Hurst SM, McLoughlin RM, Monslow J, Owens S, Morgan L, Fuller GM, Topley N, Jones SA
    J. Immunol., 2002;169(9):5244-51.
    Species: N/A
    Sample Types: N/A
    Applications: ELISA (Standard)
  35. Gp130 activation by soluble interleukin-6 receptor/interleukin-6 enhances osteoblastic differentiation of human bone marrow-derived mesenchymal stem cells.
    Authors: Erices A, Conget P, Rojas C, Minguell JJ
    Exp. Cell Res., 2002;280(1):24-32.
    Species: Human
    Sample Types: Whole Cells
    Applications: Bioassay

FAQs

No product specific FAQs exist for this product, however you may

View all Proteins and Enzyme FAQs

Reviews for Recombinant Human IL-6R alpha Protein

Average Rating: 5 (Based on 1 Review)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%

Have you used Recombinant Human IL-6R alpha Protein?

Submit a review and receive an Amazon gift card.

$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image

$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image

Submit a Review

Filter by:


Recombinant Human IL-6 R alpha Protein
By Anonymous on 02/21/2018
Application: Binding assay/Protein-protein interaction